NanoVibronix Secures Major Commitment with Ultra Pain Products
NanoVibronix, Inc. (NASDAQ: NAOV), a leading medical device company, recently announced an exciting extension of its distribution agreement with Ultra Pain Products, Inc. (UPPI). This strategic move ensures the continued distribution of its revolutionary PainShield product, marking a significant milestone in the company’s efforts to expand its reach within the healthcare market.
The Agreement and Its Impact
The renewed agreement spans five years and includes a minimum purchase commitment valued at $12 million. Brian Murphy, the CEO of NanoVibronix, shared his enthusiasm for this partnership, highlighting UPPI’s impressive growth and its alignment with NanoVibronix's goals. His remarks reveal a shared vision of innovation aimed at enhancing patient care through advanced therapeutic devices.
Understanding PainShield: A Key Product
PainShield represents a pivotal advancement in non-opioid pain management. By utilizing patented low-intensity surface acoustic wave (SAW) technology, the device produces ultrasonic waves that help alleviate pain. Patients can utilize PainShield in the comfort of their homes, making treatment more accessible and effective.
Growth of UPPI in Pain Management
UPPI has transformed into a key player in the industry over the past few years by emphasizing the importance of non-opioid treatment options. The partnership with NanoVibronix signifies not just a business agreement but a commitment to improving patient outcomes in pain management. Together, they are well-positioned to lead the charge against traditional pain treatment methods that often involve opioid prescriptions.
Employees and Stakeholders Celebrate the Collaboration
Ari Alayev, President of Ultra Pain Products, expressed gratitude for the opportunity to continue working alongside NanoVibronix, stating that their collaboration strengthens both organizations' influence in the market. This agreement is a testament to the trust and successful joint efforts over their four years of partnership. UPPI’s commitment to offering innovative technologies will be enhanced by PainShield's capabilities.
Commitment to Patient-Centric Solutions
Both companies are focused on a mission that prioritizes safety, efficacy, and affordability in pain management solutions. The ongoing collaboration allows them to leverage each other's expertise, ensuring that patients receive the best care possible through advanced treatment options. Their goal is to bridge the gap in the market where patients require safe and effective non-opioid therapies.
About NanoVibronix, Inc.
Headquartered in Tyler, Texas, NanoVibronix, Inc. (NASDAQ: NAOV) dedicates itself to the development of medical devices that feature innovative low-intensity surface acoustic wave technology. This technology is designed to create low-frequency ultrasound waves for various medical applications, promoting wellness and recovery. NanoVibronix’s products, including PainShield and UroShield, can be easily administered at home, facilitating a patient-friendly approach to treatment.
The Future of Pain Management with NanoVibronix
As NanoVibronix continues to expand its product line and strengthen relationships with distributors like UPPI, the company is poised to make substantial contributions to the healthcare landscape. With ongoing advancements in technology and a focus on patient-centered solutions, patients can expect enhanced treatment options that prioritize their needs and well-being.
Frequently Asked Questions
What is the main product of NanoVibronix?
NanoVibronix’s main products include PainShield and UroShield, which are designed for pain management and various medical applications using innovative ultrasonic technology.
How long is the renewed agreement with UPPI?
The renewed distribution agreement with Ultra Pain Products is for five years, emphasizing the commitment to advancing non-opioid pain management solutions.
What technology does PainShield utilize?
PainShield utilizes patented low-intensity surface acoustic wave (SAW) technology to produce ultrasonic waves that aid in pain relief.
Why is UPPI considered a good partner for NanoVibronix?
UPPI's growth in the non-opioid market, its commitment to innovation, and its ability to provide effective solutions make it an ideal partner for NanoVibronix.
Where is NanoVibronix, Inc. headquartered?
NanoVibronix, Inc. is headquartered in Tyler, Texas, with research and development operations located in Nesher, Israel.
